Shares of TherapeuticsMD TXMD moved higher by 2.5% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share increased 7.69% year over year to ($0.12), which beat the estimate of ($0.14).
Revenue of $19,342,000 declined by 18.46% year over year, which beat the estimate of $15,330,000.
Outlook
TherapeuticsMD hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Nov 09, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/2wxgyncb
Price Action
52-week high: $2.96
52-week low: $0.85
Price action over last quarter: down 25.15%
Company Description
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
